Autor: |
Wenlin Wu, Jie Hong, Yanping Ran, Wenxiao Wu, Haixia Zhu, Chi Hou, Yuanyuan Gao, Yulin Tang, Yinting Liao, Wen-Xiong Chen, Xiaojing Li |
Jazyk: |
angličtina |
Rok vydání: |
2024 |
Předmět: |
|
Zdroj: |
Heliyon, Vol 10, Iss 23, Pp e40680- (2024) |
Druh dokumentu: |
article |
ISSN: |
2405-8440 |
DOI: |
10.1016/j.heliyon.2024.e40680 |
Popis: |
Ofatumumab (OFA) is an anti-CD20 antibody. We assessed the therapeutic potential of OFA in five pediatric anti-NMDAR encephalitis patients who showed poor responses to the first-line immunotherapy. OFA treatment showed clinical improvement including alleviation of clinical symptoms and mRS decrease accompanied by anti-NMDAR antibody turning negative in 3 patients and decline in 2 patients. And all patients achieved B cell depletion after OFA treatment. During follow-up, all patients’ symptoms were stable. OFA treatment is safe and effective, easy to administer, and favorable for pediatric anti-NMDAE encephalitis patients who are refractory to the first-line immunotherapy. |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|